Sample characteristics
We included 81 participants from the ADNI3 study (https://clinicaltrials.gov/ct2/show/NCT02854033) all with available baseline resting-state fMRI and longitudinal AV1451 tau-PET data. The sample included 28 CN Aβ− as a healthy reference group, and 32 CN Aβ+ as well as 21 MCI Aβ + covering the pre-dementia AD spectrum (see Table 1 for baseline demographics). Mean tau-PET follow-up time was 1.3 ± 0.52 years in CN Aβ− and, 1.27 ± 0.46 years in CN Aβ+ and 1.37 ± 0.57 years in MCI Aβ+. No significant differences in tau-PET follow-up time were found across groups (p = 0.817, ANOVA). As an independent validation sample, we included 57 subjects from the BioFINDER study with available longitudinal AV1451 tau-PET data (Table 1). This sample included 16 CN Aβ−, 16 CN Aβ+, 7 MCI Aβ+ and 18 subjects with AD dementia (Aβ+). Mean…
